Stockwinners Market Radar for April 30, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

17:34 EDT GSE Systems appoints Ravi Khanna CEO - GSE Solutions announced a transition of the company's management team. Ravi Khanna has been named president and CEO of the company and appointed as a Class II Director of the board, effective immediately. Khanna has been with GSE since 2016 as its senior VP of Professional Services. Kyle Loudermilk has submitted a letter of resignation to the board and will remain with the company through May 31 to assist in a seamless transition.

17:28 EDT Starbucks says working to address overnight and weekend demand potential - CEO Narasimhan says: "I also want to talk about unmet overnight demand. We see it as a tremendous and untapped incremental opportunity. Last quarter, we mentioned we were conducting a pilot program to serve customers overnight between 05:00 p.m. and 05:00 a.m. when our stores are traditionally closed. During this pilot test, we doubled our business. Building off that success, we are aggressively pursuing options to build a $2 billion business over the next 5 years. Overnight opportunities are incremental and create a complement to our existing delivery business, which grew by double digits in the U.S. this quarter with both ticket increase and transaction growth. In addition to the overnight, we have unmet weekend demand potential."

17:26 EDT Starbucks CEO sees 'three execution opportunities' in U.S. business - CEO Narasimhan says: "There are 3 execution opportunities in our U.S. business I want to expand on: First, meet the demand we have across dayparts to drive future growth; second, launch even more exciting and relevant new products while maintaining our focus on core coffee forward offerings; and third, reach and demonstrate more value for our occasional and non-Starbucks Rewards customers. We understand how to do this and we have what we need to deliver against our plans. So as we look to the second half of the fiscal year and beyond, we're accelerating our work on the underlying execution engines that power our business to realize these opportunities."

17:23 EDT Starbucks says remain confident in Middle East long term growth opportunity

17:20 EDT Starbucks says comps decline drivn by declining traffic, negative comps in China - CEO Laxman Narasimhan says: "Our global comparable store sales declined 4% year-over-year, driven by a negative 3% comp growth in North America, led by declining traffic and a negative 11% comp growth in China." Comments taken from Q2 earnings conference call.

17:22 EDT DigitalOcean to replace Agiliti in S&P 600 at open on 5/7 - Thomas H. Lee Partners L.P. is acquiring Agiliti in a deal expected to be completed on or about that date pending final conditions.

17:17 EDT Paccar raises quarterly dividend to 30c from 27c per share - The dividend will be payable on June 5, 2024, to stockholders of record at the close of business on May 15, 2024.

17:06 EDT Starbucks down 10% at $79.84 after below-consensus Q2 revenue and earnings

17:05 EDT FuboTV says Warner Bros networks to leave Fubo as of April 30th - The company states: "Fubo (FUBO) has attempted to renew with Warner Brothers Discovery (WBD) our Discovery content agreement for its networks including Discovery, HGTV, Food Network and TLC, among others, and to obtain license rights for its Turner sports networks TNT, TBS and truTV. Fubo offered Warner Brothers Discovery market rates for its content and, despite Fubo's efforts to negotiate in good faith, Warner Brothers Discovery did not provide any counteroffer, and insisted on continuing to offer us above-market rates for its content. Fubo views Warner Brothers Discovery's refusal to engage in good faith negotiations as another example of its abuse of massive market power that ultimately limits consumer choice. It is always Fubo's mission to offer a leading package of premium sports, news and entertainment content while also providing value and keeping costs as low as possible for consumers. Warner Bros. Discovery has also denied our customers the choice of subscribing to their Turner sports content separately from Discovery content through a more affordable skinny sports bundle. Yet Warner Bros. Discovery has announced that it plans to make this must-have content available in its forthcoming sports streaming joint venture with The Walt Disney Company and FOX Corp. Warner Bros. Discovery's refusal to offer Fubo standard market terms and packaging flexibility are more examples of the unfair and anti-competitive practices it and other vertically integrated media companies have imposed on Fubo for many years. These practices, outlined in our recent antitrust lawsuit filed against the joint venture companies, aim to monopolize the market, stifle any form of competition, create higher pricing for subscribers and cheat consumers from deserved choice. Fubo is taking action against these unfair market terms to avoid passing on these extra costs to consumers. It is clear to us that Warner Bros. Discovery's actions hurt consumer wallets and limit their choice. As a result, Warner Bros. Discovery networks have left Fubo as of April 30, 2024 at 5pm ET."

16:49 EDT Diamondback Energy sees FY24 net production - 458 - 466MBOE/d - Sees FY24 Oil production - 270 - 275MBO/d.

16:42 EDT Resideo and BGE announce new partnership - Resideo Technologies and Baltimore Gas and Electric, or BGE, the largest electric and natural gas utility company in Maryland, announced a new partnership to expand BGE's Connected Rewards program, allowing more customers to play an important role in proactively balancing the grid by reducing the overall demand for electricity during periods of peak usage. Every day, over one million BGE customers use electricity to power their day. Occasionally, the demand for electricity is exceptionally high which may lead to higher energy costs. Resideo and BGE will work together to predict, identify and proactively react to peak demand events and optimize energy use, all while maintaining customer comfort.

16:40 EDT Powell: Industrial end markets activity seen supporting growth into FY25 - Commenting on the Company's outlook, Michael Metcalf, Powell's Chief Financial Officer, said, "We continue to expect another strong year of financial performance in Fiscal 2024 as our core Industrial end markets, as well as our Electric Utility and Commercial and Other Industrial markets, are exhibiting favorable dynamics and activity levels to support our growth. The quality and duration of our backlog, in conjunction with the level of commercial activity, also support our expectation that this strong financial performance can be sustained throughout Fiscal 2024 and into Fiscal 2025. Our capacity initiatives focused on servicing current and future backlog remain on track and are progressing as planned, with our Gulf Coast fabrication yard expansion now fully utilized and helping to support the execution of our $1.3 billion backlog. We expect to complete the current capacity expansion initiative at our products factory in Houston by mid-Fiscal 2025, which will help to enable our initiatives to facilitate future growth."

16:37 EDT Clorox reports Q3 gross margin up 40 bps to 42.2% from 41.8% last year - Gross margin increased 40 basis points to 42.2% from 41.8% in the year-ago quarter, primarily driven by the benefit of pricing and cost savings, partially offset by higher manufacturing and logistics costs, unfavorable foreign exchange rates and higher trade promotion spending.

16:35 EDT Hain Celestial announces strategic actions - Hain Celestial Group announced strategic actions the company is taking to progress the Focus pillar of its Hain Reimagined business strategy. Key initiatives include category-wide SKU reductions, consolidation of its operating footprint, and streamlining its co-manufacturing network, globally. The steps Hain has taken are unlocking annualized savings, generating operating cash flow to pay down debt and driving gross margin expansion. Hain Celestial Takes Strategic Actions to Simplify Portfolio & Operating Footprint to Strengthen Balance Sheet. Hain is designing a winning portfolio by actively assessing and streamlining its brand portfolios. Since July 2023, the company has removed 6% of its SKUs globally and is expected to increase that number over the next two years. Today, those reductions are split almost equally between North America and International and include brands across the Snacks, Baby/Kids, Beverages, Meal Prep and Personal Care categories. Hain is also streamlining its operating footprint and leveraging synergies across the business to drive scale as the company focuses in five core geographies: the U.S., Canada, UK, Ireland and Western Europe. As Hain is in the foundational year of its Hain Reimagined strategy, the company is continuing to identify opportunities to further simplify and streamline the business through optimizing its operating model, leveraging synergies and scale and continuing to focus on shaping a winning portfolio.Hain will share more details during the Q3.

16:33 EDT First Business Financial announces $5M share repurchase program - First Business Financial Services announced its board of directors has approved a $5.0 million share repurchase program. This program authorizes the repurchase of shares of the Company's common stock as part of its ongoing capital management strategy. The share repurchase program has no expiration date. While First Business Bank has experienced robust balance sheet growth and does not currently intend to execute on the share repurchase program, the Company believes it is prudent to have such a program in place. This allows for flexibility in capital management and the ability to enhance shareholder value, by repurchasing Company shares if and when appropriate. Corey Chambas, President and CEO of First Business Bank, commented on the announcement, "Our strong balance sheet growth is a testament to the hard work and dedication of our team. While we have no immediate plans to utilize the new share repurchase program, we believe it is sound capital management to have this option available." Under the new share repurchase program, certain officers of the Company are authorized to direct the repurchase of Company shares in such quantities, at such prices and on such other terms as they determine in their discretion to be in the best interests of the Company and its shareholders, up to a maximum aggregate purchase price of $5 million, in accordance with applicable banking and securities regulations. The Company anticipates that it will, at the appropriate time, enter into a Rule 10b5-1 trading plan, which will allow the Company to effectuate repurchases under the program during periods in which the Company and its directors and officers are or may be deemed to be in possession of material nonpublic information, provided that such officers may enter into a Rule 10b5-1 trading plan only at such time as the Company and its directors and officers are not actually in possession of material, non-public information.

16:23 EDT Manchester United says interim CEO, CFO to leave club at end of season - Manchester United plc announced it has made two further changes to its executive leadership. "By mutual consent, Patrick Stewart, interim Chief Executive Officer, and Cliff Baty, Chief Financial Officer, have decided to leave the club at the end of the season. Patrick will be replaced as CEO by Jean-Claude Blanc until the arrival of Omar Berrada on July 13th. Cliff Baty will be replaced as CFO by Roger Bell," the company stated. Joel Glazer said: "I would like to thank Patrick and Cliff for their dedicated service to Manchester United and wish them well for the future. Both have been a source of invaluable advice and expertise over many years, and Patrick has served an important role as interim CEO during this transitional phase." Sir Jim Ratcliffe commented: "I would like to personally thank both Patrick and Cliff for their support in helping us get to know the club and making us feel welcome and I respect their decisions to now move on as we establish a new management team for the club."

16:24 EDT Invitation Homes enters into JV with Lennar's Quarterra - Invitation Homes (INVH) announced that it has entered into a joint venture with Quarterra Group Inc., a wholly-owned subsidiary of Lennar Corporation (LEN), Centerbridge Partners, L.P., and other high quality institutional investors. As part of their agreement, Invitation Homes has acquired a minority equity interest in a portfolio of single-family homes for lease that are part of the Upward America joint venture. Upward America has selected Invitation Homes to provide management services to the 4,400 homes located primarily within Florida, Texas, and the Carolinas.

16:17 EDT Clearway Energy announces CEO Chris Sotos resigns, Cornelius, succeeds - Clearway Energy announced that effective June 30 Chris Sotos will move on from his position as Clearway Energy, President and Chief Executive Officer and resign from his role as a member of CWEN's Board of Directors to pursue other opportunities. Craig Cornelius, who is currently the CEO of the Company's sponsor, Clearway Energy Group will succeed Mr. Sotos as CWEN's CEO and will join CWEN's Board of Directors.

16:13 EDT Matson sees FY24 consolidated operating income modestly higher than last year - Matt Cox, Matson's Chairman and CEO, commented, "Currently in the Transpacific marketplace, we continue to see steady U.S. consumer demand, which we expect to lead to improving demand for Matson's CLX and MAX services in 2024 as compared to 2023. Absent a significant change in the trajectory of the U.S. economy, we expect trade demand dynamics across most of our domestic tradelanes in 2024 to be comparable to 2023 as consumer-related spending is expected to remain largely stable. For Ocean Transportation in 2024, we expect operating income to be higher than the prior year's result and higher than the previous outlook. For Logistics in 2024, we continue to expect challenging business conditions for transportation brokerage and expect lower year-over-year operating income. As such, we now expect full year consolidated operating income to be modestly higher than the level achieved in 2023."

16:07 EDT Starbucks reports Q2 active U.S. rewards membership totals 32.8M, up 6% y/y - Starbucks Rewards loyalty program 90-day active members in the U.S. totaled 32.8 million, up 6% year-over-year, the company said.

16:05 EDT Gulfport Energy reports Q1 production 1,053.7 MMcfe per day - John Reinhart, CEO, commented, "Gulfport started the year strong, highlighted by the improvement in operational efficiencies leading to capital spending below analyst expectations, robust adjusted free cash flow generation allowing us to continue returning capital to shareholders through our common stock repurchase program and continued strong performance from the Company's initial Marcellus development on our stacked pay acreage in Belmont County, Ohio."

16:04 EDT Amazon reports Q1 AWS net sales $25.04B vs. $21.35B last year - Amazon reports Q1 AWS operating income of $9.42B vs. $5.12B last year.

13:55 EDT Millennium Space Systems awarded $414M Space Development Agency contract - The Space Development Agency awarded Millennium Space Systems, a Boeing company, an award with a total potential value of $414M to deliver the Fire-control On Orbit-support-to-the-war Fighter, also known as FOO Fighter, or F2, the company announced. "As the end-to-end operational prime, Millennium Space Systems will deliver a constellation of eight satellites with a ground system and perform mission operations," the company stated.

13:31 EDT Highest Performances Holdings Inc (ADR) trading resumes

13:28 EDT ISS recommends Whitestone REIT shareholders vote for Erez nominee Bruce Schanzer - Erez Asset Management, which has nominated two candidates for election at Whitestone's upcoming 2024 Annual Meeting of Shareholders, announced that Institutional Shareholder Services has recommended shareholders vote on Erez's BLUE proxy card "FOR" Erez nominee Bruce Schanzer and "WITHOLD" from Whitestone nominee Nandita Berry. ISS concluded that Erez "has made a compelling case that a degree of change is needed that departs from the [incumbent] board's insular approach to refreshment and to improve transparency with shareholders." In reaching this conclusion, ISS indicated that it believed "the board also made a number of questionable governance decisions in recent years."

13:05 EDT Third Point lists Meta, Amazon among Q1 winners, starts position in Advance Auto - In its Q1 investor letter, a copy of which was obtained by The Fly, Third Point stated: "During the First Quarter, Third Point returned 7.8% in the flagship Offshore Fund. The top five winners for the quarter were Meta Platforms (META), Vistra (VST), Amazon.com (AMZN), Bath & Body Works (BBWI) and Microsoft (MSFT). The top five losers for the quarter, excluding hedges, were Pacific Gas & Electric (PCG), DuPont de Nemours (DD), Humana (HUM), Marvell Technology (MRVL) and a Short Position... During the quarter, we added to our TSMC (TSM) investment, which we initiated in May of last year. TSMC is coming off its worst year since the Global Financial Crisis, and in the years to come we see a combination of cyclical recovery plus structural growth in AI demand fueling substantial earnings growth for the company... We initiated a position in Advance Auto Parts (AAP) in Q4 2023 at an attractive entry point, after the third consecutive guidance cut of the year overshadowed new CEO Shane O'Kelly's strategic plans to course correct the business... While Advance has significantly underperformed peers across key KPIs over the past several years, our work suggests that many of these shortcomings aren't structural."

12:10 EDT ISS recommends majority of Norfolk Southern board nominees - Norfolk Southern Corporation Tuesday announced that Institutional Shareholder Services has recommended shareholders support a majority of its director nominees, reflecting a clear endorsement of the company's management and strategy. The company said, "ISS's recommendation in favor of a majority of our director nominees underscores the strength and effectiveness of our board, and the ongoing and effective execution of the company's strategy. Specifically, ISS acknowledges that, "[t]he prevailing strategy appears to be logical, particularly when considered alongside evolving views on rail service..."1 Under Alan's leadership, Norfolk Southern is accelerating a strategy that balances service, productivity, and growth, with safety at its core, and will deliver top-tier revenue and earnings growth with industry-competitive margins. At this critical point in Norfolk Southern's transformation, replacing members of our board with Ancora's inferior nominees would impede this progress, introduce significant risk, and ultimately destroy long-term shareholder value. ISS's recommendation against Jim Barber is a clear indication that a change in management is not warranted, and further, adding him to the board may create an unfavorable dynamic in the boardroom that would impede the Company's progress and momentum. All of Norfolk Southern's director nominees collectively add a wealth of highly relevant experience in the railway and transportation sectors, and important operations, safety, sustainability, risk management, and government regulation expertise. Our highly engaged board is fit-for-purpose to oversee the execution of Norfolk Southern's balanced strategy, enhance safety and operational performance, and drive smart and sustainable long-term growth for our shareholders. While ISS has recognized the strengths of our crisis-tested CEO Alan Shaw, along with independent directors John Huffard, Claude Mongeau, Richard Anderson, Philip Davidson, Francesca DeBiase, Marcela Donadio, and Christopher Jones - we disagree with ISS's recommendation as it relates to certain members of Ancora's slate. The ISS recommendation relating to Ancora's nominees jeopardizes the election of Norfolk Southern's board candidates who are critical to the effective oversight of the company, including Amy Miles, Heidi Heitkamp, Thomas Kelleher, Jennifer Scanlon, and John Thompson."

12:01 EDT E2open rises 15.6% - E2open is up 15.6%, or 67c to $4.92.

12:00 EDT Bakkt falls -17.0% - Bakkt is down -17.0%, or -$1.69 to $8.27.

12:00 EDT Chegg falls -26.2% - Chegg is down -26.2%, or -$1.88 to $5.29.

11:02 EDT Richardson Electronics enters partnership with Suzlon Energy - Richardson Electronics announced a strategic partnership with Suzlon Energy Limited, India's largest renewable energy solutions provider. Richardson Electronics will develop pitch energy modules for Suzlon's global fleet of wind turbines, a testament to their engineered solutions expertise and commitment to advancing renewable energy solutions. Suzlon has over 12,000 wind turbines worldwide with over 9,000 in India.

11:01 EDT Walmart opens consolidation center in Minooka, Illinois, creating 700 new jobs - Walmart announced the opening of its newest high-tech consolidation center in Minooka, Illinois. The new 492,000 square-foot facility will bring nearly 700 additional jobs to the area, Walmart said, adding that once implemented, the facility's automated technology can enable three times more volume to flow throughout the center. This building will be the third of its kind in Walmart's supply chain. "We've made continued investments in our people, facilities and technology to ensure we have the right product, in the right place, at the right time," said Mike Gray, Senior Vice President of Ambient Operations at Walmart. "As part of these investments, the Minooka facility will provide even more opportunities for small to medium sized suppliers in the region who do not ship nationwide, the ability to provide product to all 4,700 Walmart stores."

10:23 EDT Mullen Automotive trading resumes

10:14 EDT Highest Performances Holdings announces supplementary agreement with White Group - Highest Performances Holdings has signed a third supplementary agreement to the strategic framework agreement previously entered into with Singapore White Group. HPH intends to provide full funding to Zhongxin International Sports Group, a wholly-owned subsidiary of White Group, when bidding for intellectual property rights of sporting events and all profit generated from these sporting events will be attributed to HPH. Both parties have agreed that White Group will sell 26.5% equity interests of Zhongxin to HPH, while final terms will be agreed by both parties in due course. HPH and White Group will jointly invest in the following sports events: Major events organized by the International Tennis Federation; and Formula 1 World Championship events in China. F1 is the world's premier car racing series, the fourth most watched event in the world and is considered one of the "big three" global sporting events, along with the Olympics and the FIFA World Cup. Investments in other major sporting events are also under negotiation, with details to be announced at a future date

10:07 EDT Sysco: January restaurant traffic down high single digits vs. prior year - Reports February and March foot traffic down low single digits. Says had expected a stronger recovery throughout the quarter.

10:03 EDT Uber Eats announces exclusive delivery partnership with Domino's in Canada - Uber Eats (UBER) announced that Canadians can now order delivery from Domino's Pizza Canada (DPZ) through the Uber Eats app. "Starting today, more than 260 Domino's locations across Ontario will be available on the Uber Eats app, with all remaining Canadian locations expected to roll out over the next four weeks," the company stated.

10:01 EDT Verizon, Houston Dynamo Football Club extend partnership agreement - Houston Dynamo Football Club and Verizon announced the extension of their 2023 partnership agreement. Verizon will serve as the official 5G partner of the Houston Dash and Houston Dynamo FC through the 2024 season. Verizon will also be the presenting partner for Fan Appreciation Weekend for both teams. During the special multi-day event this fall, Houston Dash and Dynamo fans will be eligible to win unique experiences as part of the festivities. Details for the celebration will be announced on the Houston Dash and Dynamo social media channels at a later date.

10:01 EDT Sensata rises 14.7% - Sensata is up 14.7%, or $5.26 to $41.02.

10:00 EDT Chegg falls -19.0% - Chegg is down -19.0%, or -$1.36 to $5.80.

09:50 EDT Perficient jumps 6% to $45.92 after Bloomberg says considering sale

09:48 EDT Coursera falls -13.2% - Coursera is down -13.2%, or -$1.56 to $10.32.

09:47 EDT Medifast falls -25.0% - Medifast is down -25.0%, or -$8.87 to $26.64.

09:47 EDT E2open rises 10.9% - E2open is up 10.9%, or 47c to $4.72.

09:37 EDT Acima Leasing enters LTO partnership with iFIT - Acima Leasing announced an exclusive LTO partnership with iFIT Inc. for iFIT's interactive fitness products on nordictrack.com and proform.com. iFIT will now be able to provide its growing community of members with flexible and convenient access to its suite of brands, such as NordicTrack and ProForm, by integrating Acima Leasing's proprietary technology solution.

09:31 EDT Philips enters 10-year collaboration with Nicklaus Children's Health System - Royal Philips and Nicklaus Children's Health System announced a 10-year long-term strategic collaboration aimed at enhancing the patient and staff experience, enhancing outcomes and driving innovation in pediatric care. Serving over 500,000 patients a year, Nicklaus Children's will adopt Philips technologies such as the Ingenia Ambition X MR and EPIQ CVx ultrasound, with AI-enabled radiology workflow solutions to reduce exam times and the need for rescans, while increasing diagnostic confidence, resulting in faster diagnosis and treatment for patients. The addition of patient experience technologies such as Philips Ambient Experience, Kitten Scanner and Scan Buddy App, will help put patients at ease during MRIs by showing them what to expect and empowering them during the scan to help reduce the need for sedation and further shortening exam times.

09:30 EDT Mars Acquisition Corp trading halted, volatility trading pause

09:29 EDT Upwork introduces Upwork update to launch AI innovations, other features - Upwork unveiled a collection of products, features and partnerships to transform how businesses and professionals hire and work, as part of Upwork Updates: Spring 2024, Upwork's new semi-annual product showcase. The Spring 2024 Update is headlined by Uma, Upwork's Mindful AI. Upwork also premiered access to new tools for freelancers to stand out, get hired, and produce their best work. Upwork introduced two new avenues for businesses to access the expertise they need to serve their most pressing needs. Upwork Enterprise introduced new vendor management system and managed service provider partnerships, alongside enhancements to the Enterprise client experience.

09:26 EDT OceanPal announces time charter contract for M/V Baltimore with Richland Bulk - OceanPal announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with Richland Bulk Pte. Ltd., for its Capesize dry bulk vessel, the m/v Baltimore. The gross charter rate is US$22,000 per day minus a 5% commission paid to third parties, for a period until minimum September 15, 2024 up to maximum November 15, 2024. The charter is expected to commence in mid-May. The m/v Baltimore is currently chartered to Richland Bulk Pte. Ltd., at a gross charter rate of US$13,500 per day, minus a 5% commission paid to third parties. The "Baltimore" is a 177,243 dwt Capesize dry bulk vessel built in 2005.

09:24 EDT Ageagle Aerial Systems announces $3.4M drone sale to French Army - AgEagle Aerial Systems announced that the Company has secured its largest single purchase order to date to deliver 40 eBee VISION systems, and nine other eBees, including drones, sensors, datalinks, and control stations placed by a reseller to the French Army, specifically tailored for public safety, intelligence surveillance and reconnaissance missions. The revenue from this system contract is expected to be approximately $3.4 million for fiscal year 2024, making this the largest contract in AgEagle's history.

09:23 EDT Ideal Power announces order from power management market leader - Ideal Power announces that the Company received an order for SymCool power modules and drivers from one of the two Forbes Global 500 leaders in diverse power management markets in Ideal Power's B-TRAN test and evaluation program.

09:22 EDT Westhaven Gold appoints Fraser Maccorquodale as technical advisor - Westhaven Gold announced the appointment of Mr. Fraser MacCorquodale as a Technical Advisor. MacCorquodale served as the General Manager of Exploration at Newcrest Mining Limited from 2008 to 2023. Westhaven has granted 200,000 incentive stock options to a consultant. The incentive stock options have an exercise price of 25 cents per share, are valid for a five-year period from the date of grant and are subject to regulatory approval. The company's stock option plan allows for the issuance of up to 10 per cent of issued and outstanding share capital in the form of incentive stock options. As a result of this grant, the company has 13,535,000 stock options issued, representing 9.1 per cent of the issued and outstanding share capital.

09:21 EDT VIctory Energy, Hyliion enter LOI to deploy up to 10 KARNO generators - Victory Clean Energy (VYEY) and Hyliion Holdings Corp. (HYLN) announced they have entered into a non-binding letter of intent. Under the terms of the agreement, Victory will purchase up to 10 KARNO generators, to be deployed in the Hydrogen production facilities of their subsidiary, H2 Energy Group. Specializing in green hydrogen production from renewable biomass, H2EG intends to utilize the KARNO generators to produce electricity using the hydrogen-rich syngas derived from the biomass to power their operations. Under the terms of the LOI, H2EG is slated to receive their first five KARNO generators in the second half of 2025, each capable of producing an estimated power output of 200 kW, with a total capacity of 1MW. H2EG also plans to leverage the KARNO generators combined heat and power capabilities and utilize the excess heat to improve efficiencies in their manufacturing process. The LOI also includes the option for H2EG to purchase an additional five KARNO generators upon the successful deployment of initial units. The LOI between Hyliion and H2 Energy Group is subject to the execution of a binding purchase agreement.

09:18 EDT NovAccess Global announces license to advance immunotherapy platform - NovAccess Global announced the procurement of a new intellectual property license from Cedars-Sinai Medical Center to further advance the Company's immunotherapy platform. The license pertains to the use of Isocitrate Dehydrogenase-1, a protein previously known to impact cell metabolism. The Company intends to leverage this license to predict a patient's likely response to vaccine immunotherapy during treatment for highly malignant brain tumors, such as glioblastoma. IDH1 is commonly mutated in brain and other tumors. Groundbreaking research published by Dr. Chris Wheeler, President and lead scientist of NovAccess Global's subsidiary StemVax, LLC, has shown that IDH1 predicts antitumor responses after vaccine therapy through a novel molecular mechanism. The Company assesses that IDH1 expression is likely to discern long-duration from short-duration survivors after vaccine therapy in patients with brain tumors such as glioblastoma. Information derived from the use of IDH1 as a biomarker will help to better inform therapeutic strategy as physicians assess the use of single agent or combination therapies in their treatment of patients facing these life-threatening diagnoses. NovAccess Global intends to support the development of IDH1 as a biomarker for TRL-AD1, its candidate drug for the treatment of cancers of the central nervous system that in 2022 received Orphan Drug designation by the U.S. Food and Drug Administration. The Company will assess IDH1 as a companion diagnostic to TRL-AD1 while exploring IDH1's potential to serve as a prognostic indicator of patient response to currently marketed therapies and those in clinical development.

09:16 EDT Biotricity announces partnerships with home-based diagnostic companies - Biotricity announces the expansion of its cardiac diagnostics portfolio through strategic partnerships with a leading home-based neurology company and a leading home-based sleep apnea diagnostic company. Individuals suffering from sleep or neurological disorders have elevated risks for cardiac issues. These collaborations position Biotricity and its partners as comprehensive providers of holistic screenings, marking a significant advancement in Biotricity's mission to offer integrated healthcare solutions that address the complex needs of patients with multiple conditions.

09:13 EDT Freddie Mac sells $5.7M in non-performing loans - Freddie Mac announced it sold via auction 20 deeply delinquent non-performing residential first lien loans from its mortgage-related investments portfolio to GITSIT Solutions, LLC. The loans, with a balance of approximately $5.7 million, are currently serviced by Specialized Loan Servicing LLC and NewRez LLC, d/b/a Shellpoint Mortgage Servicing. The sale is part of Freddie Mac's Extended Timeline Pool Offering and the transaction is expected to settle in June 2024. Freddie Mac, through its advisors, began marketing the transaction on March 6, 2024, to potential bidders, including non-profit organizations and Minority, Women, Disabled, LGBTQ+, Veteran or Service-Disabled Veteran-Owned Businesses, neighborhood advocacy organizations and private investors active in the NPL market. Given the delinquency status of the loans, the borrowers have likely been evaluated previously for loss mitigation, including modification or other alternatives to foreclosure, or are in foreclosure. Mortgages that were previously modified and subsequently became delinquent comprise approximately 27 percent of the aggregate pool balance. Additionally, purchasers are required to honor the terms of existing loss mitigation agreements and solicit distressed borrowers for additional assistance except in limited cases and ensure all pending loss mitigation actions are completed.

09:12 EDT LNG Energy reports 2024 objectives - The company said, "For the remainder of 2024, LNG Energy Group is focused on the following objectives: Colombia In Colombia, the Company expects to complete the following: a workover and optimization program targeting four to six wells; drill one development well in the producing Bullerengue field in the Sinu-San Jacinto-1 Block; drill two to four exploration wells in the SSJN-1 and Perdices Blocks; continuing to evaluate and strengthen the Corporations's commitment to environmental, social and governance initiatives; and the repayment of its indebtedness and strengthening of its capital and liquidity resources. For more information, please see the Company's news release dated March 5, 2024. Venezuela: On April 17, 2024, LNG Energy Group's wholly own subsidiary, LNGEG Growth I Corp. was conditionally entered into a binding agreement with PDVSA Petroleo S.A., a subsidiary of Petroleos de Venezuela S.A., the Venezuelan national oil company, for the operation of the Nipa-Nardo-Niebla and the Budare-Elotes CPPs in onshore Venezuela. These Blocks are currently producing 3,000 bbl/d of light and medium oil. The CPPs were executed within the term of General License 44 issued by the US Office of Foreign Assets Control. License 44 has been replaced by License 44A requiring US persons to wind down oil operations in Venezuela before May 31, 2024. The Corporation will assess in the coming days the applicability of License 44A to its intended operations in Venezuela and determine the most appropriate course of action. The Corporation intends to operate in full compliance with the applicable sanction regimes. For more information, please see the Company's news release dated April 24, 2024."

09:10 EDT LivaNova announces Ahmet Tezel as chief innovation officer - LivaNova announced Ahmet Tezel will join the company as chief innovation officer, effective May 13. In this newly created position, Tezel will leverage his career of more than 20 years in research and development to establish an integrated innovation function at LivaNova that will accelerate the company's development of new technologies. In this capacity, Tezel will join the LivaNova executive leadership team.

09:09 EDT Roku expands measurement partnership with iSpot.tv - Roku announced an expanded measurement partnership with iSpot.tv, the cross-platform TV measurement company. The first-of-its-kind arrangement is multifold, with each company sharing measurement capabilities to drive innovation, opportunity, and advertiser value within the broader streaming TV ecosystem...As part of the expanded partnership, iSpot will become a preferred third-party measurement partner for Roku, offering direct and programmatic advertisers fast, reliable metrics that demonstrate the unique reach, frequency, verified ad exposures, and outcomes delivered across ads running on the Roku platform. In addition, iSpot will integrate Roku's Advertising Watermark to validate the authenticity of video ad inventory originating on the Roku platform. iSpot will gain access to Roku's exclusive, authenticated audience information. These assets will strengthen iSpot's ability to connect audiences deterministically across linear TV and streaming on Roku. The partnership will bolster iSpot Data Connect, its next-generation audience measurement infrastructure, which powers currency and outcome measurement for the industry.

09:07 EDT WW to host live virtual event with Oprah Winfrey - WW International announced a live virtual event, hosted by Oprah Winfrey, "Making The Shift: A New Way to Think About Weight." The event will take place on Thursday, May 9, from 6 to 9 p.m. ET, and will include a live studio and live global virtual audience, and will be live streamed on WeightWatchers YouTube channel. Joining the conversation are diverse and influential voices, including Rebel Wilson, Amber Riley, Katie Sturino, Marisa Meltzer, Jamie Kern Lima, Tressie McMillan Cottom, along with leading science and medical experts, Dr. Rachel Goldman, Dr. Ania Jastreboff and Dr. Stephan Guyenet, who will help us dismantle the current diet culture, as we lean into science and the exciting evolution of weight and our health. The honest and brave dialogue will allow us the space to reconcile our varying thoughts on diet culture, weight bias and much more. For an opportunity to join the conversation with Oprah and guests and interact as part of the live virtual audience, participants are invited to register for the event in advance. Throughout the three-hour event, Oprah will guide a conversation to catalyze a new wave of change in how we collectively redefine the cultural and personal relationships between our weight, our health and each other. The powerful discussion will unpack the multifaceted, preconceived notions we have about weight, from the profound impact diet culture has had on our society to how we can reframe harmful narratives surrounding our weight and our bodies. Together with WeightWatchers, the conversation will bring together the voices of individuals, communities and medical societies to bridge the science of "weight" with a new outlook that brings the health and wellbeing of our bodies into focus.

09:06 EDT ALX Oncology announces initiation of Phase 2 trial in patients with HPVOC - ALX Oncology Holdings announced the initiation of a Phase 2 investigator-sponsored trial of neoadjuvant radiation and evorpacept, a next-generation CD47 blocker, in combination KEYTRUDA in patients with previously untreated and early-stage locally advanced, resectable, human papillomavirus-mediated oropharyngeal cancer. This multi-center, single-arm, open-label Phase 2 IST is being led by Joseph A. Califano III, M.D., Director of the Hanna and Mark Gleiberman Head and Neck Cancer Center at the University of California, San Diego.

09:05 EDT Zuora acquires 'metering and rating solution Togai,' terms undisclosed - Zuora announced its planned acquisition of metering and rating solution Togai, "enhancing its usage-based offerings. With Togai's low-code builder and developer-friendly interface to quickly configure metering and rating of raw events, the acquisition will help Zuora unite developers and finance teams to launch, iterate and adapt usage-based models...," said the release..."Developers spend months building internal metering and rating systems, which can quickly evolve into a dedicated team of engineers as companies realize that building a usage-based billing system is not a one-time effort. Togai makes it possible to go live in hours with an out-of-the-box, flexible solution to model any type of pricing and reliably scale," said Abhishek Rajagopal, CEO and Co-founder at Togai. "Combining Zuora and Togai is the right decision to bring together deep metering and rating with the scale of Zuora's end-to-end monetization technology." The acquisition of Togai is expected to close in early May 2024 and is subject to customary approvals and closing conditions. Foros is acting as financial advisor and Freshfields Bruckhaus Deringe as legal advisor to Zuora. QED Corporate Advisors is acting as financial advisor and Argus Partners as legal advisor to Togai

09:04 EDT Wearable Devices, Webidoo join forces for Mudra Band's retail rollout - Wearable Devices announces a collaboration with Webidoo, through Webidoo Store, an experience retail store in Milano, Italy, showcasing the latest in technology, innovation and gadgets. In this collaboration, the Mudra Band will be featured in Webidoo Store's offering customers the unique opportunity to experience and assess the product firsthand. Concurrently, for those who favor the convenience of digital shopping, the Mudra Band will also be made available through Webidoo's online store, ensuring a comprehensive purchasing option for all consumers. This partnership brings the Mudra Band into the realm of experiential retail, powered by Webidoo Stores' expertise in delivering cutting-edge technology products directly to consumers.

09:03 EDT GigaCloud expands global fulfillment network - GigaCloud Technology announced its global fulfillment network has surpassed 10 million square feet of total space following the signing of a new lease in Ontario, California. This expansion strengthens GigaCloud's ability to support the continued growth of its B2B marketplace and deliver enhanced fulfillment support to its B2B marketplace participants. The new Ontario fulfillment center, spanning approximately 562,100 square feet, is set to commence operations in July 2024. With this latest addition, GigaCloud's global fulfillment network, comprising strategically positioned fulfillment centers and other facilities designed for efficient inventory management and order fulfillment, expands to 42 locations with over 10.5 million square feet - an increase of 169% from approximately 3.9 million square feet as of March 31, 2023.

09:02 EDT Civista Bancshares appoints Ian Whinnem as CFO - Civista Bancshares appointed Ian Whinnem as SVP, CFO effective June 3. Whinnem joins Civista with over 25 years of corporate finance management in banking, including the past seven years as SVP, Director of Profitability Management and Capital Utilization for Huntington Bancshares. He began his career with FirstMerit Corporation in 1998 and held various finance roles including Director of Finance, prior to Huntington's acquisition of FirstMerit in 2016.

09:01 EDT Safe and Green expects to close sale of St. Mary's site in May - Safe and Green Development entered into an amendment to its original contract for the sale of its St. Mary's site to extend the closing date. After evaluating the current timeline, the closing of this transaction is expected by May 30, 2024, with the transaction potentially concluding as early as May 15th. This transaction will yield in excess of $1M in non-dilutive capital, bolstering the Company's operational capabilities. Furthermore, the Company announced that the closing for this transaction will take place via SG Devco's online real estate market platform, Xene Home. This platform offers a seamless and secure digital experience, seeking to revolutionize the way real estate transactions are conducted.

09:00 EDT Grom Social Enterprises enters definitive documents phase of Arctic7 acquisition - Grom Social Enterprises has entered the definitive documents draft phase for its slated acquisition of Arctic7, Inc. (Arctic7.com), the emerging Texas-based gaming industry service provider. The pending deal was announced jointly by both companies in March as the companies entered into a non-binding letter of intent. Upon completion of the transaction, Arctic7's gaming development and virtual production services would be offered alongside Grom's current portfolio of kids' and family entertainment, social media and educational services. The move into definitive documents was confirmed by Darren Marks, Grom's CEO. The acquisition of Arctic7 will introduce Grom to the growing and lucrative gaming industry, estimated at $180B and allow Grom to explore synergies across its suite of offerings, which primarily cater to the entertainment demands of today's families. Next year, Grom's Curiosity Ink Media division will debut two co-productions, a feature film, Santa.com, and an original preschool series, Hey Fuzzy Yellow! - both slated for international distribution. These premiere franchises are the first film and TV series to come out of Grom's growing catalog of original intellectual property. Looking forward, Arctic7 is anticipated to operate as a division within Grom and will continue to execute against its current strategy of delivering exciting and engaging experiences for players and partners. In the coming weeks and months, Grom and Arctic7 intend to explore partnership opportunities and titles presented by the Grom acquisition.

08:58 EDT Inuvo announces enhancements to Audience Discovery Portal - Inuvo announces a significant enhancement to its Audience Discovery Portal, the latest version of a first-of-its-kind intelligence capable of instantly generating marketing audience insights. Powered by IntentKey AI, a proprietary large language model designed specifically to find and target audiences without using identifiers like cookies or consumer data, the portal can now incorporate and appropriately associate trending and transient knowledge into its audience discovery abilities, offering a new approach to AI-driven marketing. One of the key improvements is the portal's ability to rapidly understand the relationships between concepts and map them together seamlessly. Inuvo's patented concept graph technology now refreshes in near-real-time. This development ensures portal users have access to the most up-to-date and relevant information.

08:57 EDT PayPal sees earnings growth more muted in 2H

08:55 EDT FSD Pharma enters agreement with ASPI to conduct unbuzzed trial - FSD Pharma entered into agreement with Applied Science and Performance Institute in Tampa, Florida, on April 24, 2024 to conduct "A Randomized, Double-Blind, Placebo-Controlled Crossover Study to Assess the Safety and Efficacy of unbuzzd in Healthy Volunteers in an Induced State of Alcohol Intoxication".

08:53 EDT Adeia enters into long-term IP license agreement with Astound Broadband - Adeia has entered into an agreement with Astound Broadband, a leading provider of digital TV, high-speed internet and phone services for residential and business customers across the United States, to license Adeia's media intellectual property portfolio. "Astound is one of the largest pay-TV and broadband providers in the country. Its leadership team has developed and maintained an exceptional reputation for developing a wide range of innovative solutions, including on-demand access to vast libraries of movies and TV shows," said Dr. Mark Kokes, Adeia's chief licensing officer and general manager, media. "Our agreement with Astound underscores our mutual commitment to delivering exceptional digital experiences. It addresses the evolving expectations of U.S. consumers by providing Astound with a license to foundational technologies as they seek to build customized and differentiated experiences for their subscribers."

08:52 EDT M2i Global upgrades to OTCQB listing - M2i Global announced its uplisting from the OTC Pink Market to the OTCQB Venture Market effective Tuesday, April 30, 2024 and will continue to trade under the ticker symbol "MTWO".

08:51 EDT LiveOne announces targeted price refinement of 50c-$1 for select offerings - LiveOne announced a targeted price refinement of $0.50-$1 for select membership offerings, significantly below recent industry benchmarks. This adjustment marks the first price change in a decade and demonstrates the company's commitment to continued innovation and progression. With over 3.7 million ad-supported and paid members, including 1.7 million Tesla owners, LiveOne is poised to capitalize on the projected growth of the music streaming market from $35 billion to over $100 billion by 2030. "We're dedicated to revolutionizing the audio experience," said Robert Ellin, CEO of LiveOne. "This strategic price raise will fuel our growth initiatives, solidify our position as a leader in audio and entertainment, and continue to offer the best value to our customers."

08:50 EDT Wave Life announces approval of first CTA for RestorAAtion-2 trial - Wave Life Sciences announced the approval of its first clinical trial application, CTA, for its RestorAATion-2 clinical trial of WVE-006, the company's first-in-class RNA editing oligonucleotide, which is being developed for the treatment of alpha-1 antitrypsin deficiency, AATD. WVE-006 is GalNAc-conjugated and subcutaneously administered; it does not use a lipid nanoparticle delivery system. "The approval of our first CTA for the RestorAATion-2 clinical trial of WVE-006 marks an important milestone as we continue extending our leadership in RNA editing. It is also important for the alpha-1 community as WVE-006 has the potential to enable correction of the disease-causing RNA mutation and provide a single therapeutic option regardless of whether patients have AATD liver disease, lung disease or both," said Paul Bolno, MD, MBA, President and Chief Executive Officer of Wave Life Sciences. "Our rapid progress in dose escalating healthy volunteers enabled us to demonstrate the translation of safety and pharmacokinetics of WVE-006 in humans and quickly identify a starting dose level that, based on preclinical data, is expected to engage the target in patients. With proof-of-mechanism data from RestorAATion-2 expected later this year, we look forward to the opportunity to provide clinical demonstration of RNA editing and proof-of-concept for our wholly owned pipeline of RNA editing candidates."

08:47 EDT GameSquare, Dairy MAX launch UEFN World Building Map Campaign - GameSquare Holdings and Dairy MAX announce their partnership to launch the UEFN World Building Map Campaign in Fortnite's Farm Tycoon. The Farm Tycoon experience, developed by Moonlight Studios, a GameSquare company powered by the full-service strategy and creative agency Zoned, allows players to step into the shoes of a dairy farmer, building and managing their own farm for success. From claiming plots to upgrading infrastructure, players will engage in activities that simulate real-world farm operations. Through strategic gameplay, they will earn in-game currency and experience points to enhance their farm's productivity.

08:45 EDT Strata Skin Sciences announces XTRAC comeback placements in Q1 of 2024 - STRATA Skin Sciences announces the placement of six XTRAC devices with dermatology clinics in the first quarter of 2024 that are considered "comebacks." Comebacks are excimer placements with dermatology clinics that were previously active in the Company's partner program, then terminated their relationship with the Company at some point in the past but have now decided to return to STRATA under the partner program. Among these comebacks are Henry Ford Health System in Detroit, Integrated Dermatology Group, and several practices from the Schweiger Dermatology Group.

08:43 EDT Melco Resorts partners with Sri Lanka's John Keells Holding - Melco Resorts & Entertainment announces its partnership with John Keells Holdings, the largest listed conglomerate on the Colombo Stock Exchange, in their $1B plus integrated resort development in central Colombo. As part of the partnership, the integrated resort, which had previously been branded "Cinnamon Life Integrated Resort", will be rebranded as "City of Dreams Sri Lanka". City of Dreams Sri Lanka will be the first integrated resort in Sri Lanka and South Asia and is expected to revolutionize luxury hospitality, entertainment, and leisure in Sri Lanka, presenting an extraordinary architecture and design and a collection of iconic and unparalleled offerings including 800 hotel rooms, retail, food & beverage outlets, MICE facilities, and much more. Additionally, a wholly-owned local subsidiary of Melco has been awarded a 20-year casino license by the Government of Sri Lanka. Melco will fit-out and operate the gaming area at City of Dreams Sri Lanka, and Melco will manage the top 5 floors of the hotel under its Nuwa brand of ultra high-end luxury rooms, which represents 113 of the 800 total hotel rooms at City of Dreams Sri Lanka. Melco and John Keells have agreed all key commercial arrangements and expect fit-out of the casino area to begin shortly. The estimated initial investment in the casino is expected to be approximately $125 million. The non-gaming facilities of the integrated resort, including the 687 key Cinnamon Life hotel managed by John Keells, is in the final stages of completion and is expected to commence operations in the third quarter of 2024, while we expect to commence casino operations in mid-2025. There is potential for further expansion of the gaming facilities, subject to performance and market conditions.

08:41 EDT Verb's MARKET.live, TikTok Shop partnership event draws over 300 attendees - Verb Technology Company held a celebratory event in collaboration with TikTok Shop on April 25, 2024, bringing together more than 300 attendees at MARKET.live's Studios just outside Los Angeles. "What an incredible event and what an extraordinary way to launch and announce a new partnership of this magnitude," said VERB CEO, Rory Cutaia. "Verb shareholders have much to be excited about."

08:40 EDT ClearSign granted order for engineering of burners for California refinery - ClearSign received two purchase orders to complete the detailed engineering of burners for the fitting of two additional process heaters in a California refinery for a total of four burners. These orders follow the recent installations of two multi burner heater orders at the customer's refinery site. Like previous orders, this initial engineering is anticipated to be followed by purchase orders for the manufacture and supply of burners.

08:40 EDT Lumine Group completes purchase of assets from Casa Systems - Lumine Group Inc. (LMGIF) announced that it has completed the acquisition of the Axyom Cloud Native 5G Core Software & RAN Assets from Casa Systems (CASA). This marks Lumine Group's 14th corporate carve-out that it has completed and set up in the communications and media space. The Assets will operate as an independent, autonomous business unit within Lumine Group under the brand name "Axyom.Core".

08:38 EDT Vaxart announces results for bivalent norovirus vaccine candidate - Vaxart has completed the topline analysis for the Phase 1 clinical trial evaluating Vaxart's oral pill bivalent norovirus vaccine candidate. The trial was focused on lactating mothers. Antibodies to norovirus rose on average 4.0 fold for the G1.1 virus strain and 6.0 fold for the GII.4 virus strain in the breast milk of lactating mothers who received the Vaxart vaccine candidate in the high dose group. There were no vaccine-related serious adverse events and no dose-limiting pharmacotoxicity. There is no approved vaccine against norovirus, which sickens approximately 21 million people in the United States each year, including the 15% of children under age 5 who contract norovirus annually. Approximately 3 million sets of parents are forced by this virus to miss work - approximately 2.2 days on average - to care for their children. The annual disease burden from norovirus is $10.6 billion in the United States alone. Globally, norovirus has become the leading cause of pediatric gastroenteritis in health care settings in countries that have adopted a rotavirus vaccine program. Pediatric deaths in the United States due to norovirus are rare, but they are much more common in the developing world. This Phase I trial was conducted in South Africa , and partially funded by the Bill & Melinda Gates Foundation. More complete results, including other immunogenicity measures, will be reported in a future scientific manuscript.

08:36 EDT Ultragenyx announces completion of enrollment in Phase 3 studies of setrusumab - Ultragenyx Pharmaceutical announced that all patients have been enrolled across the Phase 3 Orbit and Cosmic studies evaluating setrusumab in pediatric and young adult patients with osteogenesis imperfecta. The pivotal Phase 3 portion of the Orbit study has randomized 158 patients ages 5 to 25 years, and the Cosmic study has completed enrollment of 66 patients ages 2 to less than7 years. Data presented at the American Society for Bone and Mineral Research 2023 Annual Meeting from the Phase 2 portion of the Orbit study showed that treatment with setrusumab reduced the median annualized fracture rate by 67% and this reduction was associated with continuing large and meaningful improvements in bone mineral density. Setrusumab was generally well tolerated with no drug-related serious adverse events reported and no reports of drug-related hypersensitivity. Additional longer-term Phase 2 safety and efficacy data from the Orbit study are expected in the second half of 2024.

08:35 EDT Processa Pharmaceuticals appoints Steven Cha as SVP, clinical research - Processa Pharmaceuticals has named Steven Cha, M.D. as Senior Vice President of Clinical Research. In this newly created position, Dr. Cha's experience as an oncologist as well as in oncology drug development will be important additions to Processa. While at Puma Biotechnology, Dr. Cha was responsible for the global Phase 3 study in HER2+ breast cancer for the combination of neratinib and capecitabine.

08:34 EDT PayPal sees free cash flow $5B in FY24, share repurchase at least $5B - Sees non-GAAP effective tax rate approximately 22%. Comments taken from Q1 earnings conference call.

08:32 EDT Global Mofy Metaverse, Heartdub develop generative video AI platform - Global Mofy Metaverse announced that its wholly-owned subsidiary, Gauss AI, has teamed up with Heartdub, a U.S.-based leader in physical simulation technology. They are jointly developing Gausspeed - a generative artificial intelligence platform designed for film production, video generation, and other content creation within the digital entertainment sector. Haogang Yang, CEO of Global Mofy Metaverse, stated, "As technology reshapes the entire filmmaking production process and entertainment experience, content creators face extensive challenges. Optimizing traditional workflows in digital entertainment through technological innovation to drive industry advancement is a shared goal among global film production companies, which represents a major opportunity and market expansion for us. Our strategic partnership with Heartdub gives us a competitive advantage, where we execute on a shared vision and leverage our combined resources and technologies, along with leaders like NVIDIA, to transform filmmaking, while creating meaningful near and long-term value for all of our shareholders."

08:30 EDT LM Funding appoints Marty Traber to board of directors - LM Funding America announced the appointment of Marty Traber to the Company's Board of Directors. Mr. Traber, who previously served as a director for the Company from 2015-2021, replaces Todd Zhang, who is retiring from the board. Traber is currently the Chairman of the Skyway Capital Markets Group, where he oversees the organization's strategic planning and growth, building on more than 40 years of experience in securities law and corporate finance.

08:27 EDT Soleno Therapeutics announces publication of data comparing DCCR treatment - Soleno Therapeutics announced the publication of the comparison of results from the Company's Phase 3 placebo-controlled study and open-label extension study evaluating investigational, once-daily DCCR Extended-Release tablets in patients with Prader-Willi syndrome, to data from the PATH for PWS natural history study, in the Journal of Neurodevelopmental Disorders. The article, entitled, "Behavioral Changes in Patients with Prader-Willi Syndrome Receiving Diazoxide Choline Extended-Release Tablets Compared to the PATH for PWS Natural History Study." Data from DCCR-treated participants in the C602/C602 cohort were compared to results from a cohort of comparable participants from PATH using the same caregiver-completed questionnaires to measure hyperphagia and PWS-related behaviors in six domains: aggressive behaviors, anxiety, compulsivity, depression, disordered thinking, and rigidity-irritability. Participants treated with DCCR showed highly statistically significant and clinically meaningful improvement with DCCR administration relative to participants in the PATH study at 6 and 12 months. As with hyperphagia, highly statistically significant and clinically meaningful improvements were seen in DCCR treated participants compared to those in the PATH study in all behavioral domains of the PWSP at 6 and 12 months.

08:26 EDT INmune Bio provides update on two patients from Phase 1b AD trial - INmune Bio shares an update on two patients from the Phase 1b trial completed in 2021 who have continued to receive XPro for treatment of Alzheimer's Disease, AD, for more than three years under the Australian compassionate use program known as the Special Access Scheme, SAS. Both patients, herein referred to as "Patient 1" and "Patient 2," was an original study participant in the Phase 1b clinical trial, in the target dose 1mg/kg cohort, which commenced in November of 2019 and completed in September of 2021. Reports from the primary care physicians indicate that XPro has been well-tolerated throughout the treatment period, with stable cognitive function observed in the patients. Furthermore, the patients express a desire to continue receiving XPro for Alzheimer's disease treatment. "We are delighted to report that according to primary care physicians treating these patients under the SAS, the long-term administration of XPro(TM) has been safe and well-tolerated with these patients maintaining stable cognitive functions for more than three years of continued XPro treatment," expressed R.J. Tesi, M.D., CEO of INmune Bio. "Given the typical progression of Alzheimer's Disease and comparative data from other drug trials, stable cognitive and physical function over this long period is encouraging."

08:24 EDT IPG Photonics appoints Gitin as new CEO - IPG Photonics announced that its Board of Directors has appointed Mark Gitin, 57, as the next Chief Executive Officer, CEO, of the Company and as a member of the Board, effective June 5, 2024. Dr. Gitin's appointment follows a robust succession planning process, which was conducted with the assistance of a leading independent search firm and considered both internal and external candidates. Following Dr. Gitin's addition, the Board will expand to 11 members. Dr. Gitin will succeed Dr. Eugene Scherbakov, 76. Dr. Scherbakov is a co-founder of IPG and has spent 30 years with the Company. He will remain a member of the Board and serve as an advisor to the newly appointed CEO.

08:23 EDT FactSet introduces AI-powered Portfolio Commentary - FactSet announced its latest GenAI advancement, Portfolio Commentary. Portfolio Commentary significantly reduces the challenging, time-consuming, and nuanced process of writing attribution summaries manually. "For over 20 years, FactSet has consistently delivered ever-improving solutions for attribution analysis. Today, we raise the bar with the introduction of Portfolio Commentary," said Chris Ellis, Executive Vice President, Head of Strategic Initiatives at FactSet. "Based on internal testing, we anticipate this enhancement will enable asset managers, asset owners, and wealth managers to reduce the time spent writing portfolio commentary by a factor of eight and thus focus on the more high-value, strategic priorities of improving performance and strengthening client relationships."

08:21 EDT Duos Technologies Group reappoints Goldfarb as CFO - Duos Technologies announced the re-appointment of Adrian Goldfarb as Chief Financial Officer, CFO, effective April 29, 2024, following the departure of Andrew Murphy who has been recruited by another company to serve as their CFO. Murphy served as Duos' CFO since November 2022 and was instrumental in the development of the finance team to support senior management in preparation for an expected growth in business.

08:17 EDT Akero Therapeutics appoints Gangloff as Chief Technology Officer - Akero Therapeutics announced the appointment of Scott Gangloff as Chief Technology Officer. Most recently, Gangloff served as Vice President, Global Biopharmaceutical Development, at Incyte Corporation

08:09 EDT Sysco appoints CEO Kevin Hourican as chair of the board - Sysco Corporation announced that the Board has appointed President and CEO Kevin Hourican to Chair of the Board of Directors. Edward D. Shirley has stepped down from his position as Chairman of the Board due to personal health reasons. Effectively immediately, Mr. Hourican will serve as Chair of the Board and CEO. Sysco also announced that Larry Glasscock has been appointed Lead Independent Director and will serve as the primary liaison between the independent directors and the CEO as well as presiding at meetings of the non-employee and independent directors. Mr. Glasscock has stepped down as Chair of the Corporate Governance and Nominating Committee and will be replaced by independent director John Hinshaw.

08:08 EDT Airgain, Mouser Electronics in pact to distribute pruducts 'to design engineers' - Airgain announced an agreement to distribute its wireless and IoT products through Mouser Electronics, an online electronic component distributor that serves the global electronic design engineer and buyer community. The new agreement will make Airgain's innovative NimbeLink embedded modems, antennas, and other wireless products more broadly available to design engineers looking to simplify wireless connectivity in their new product designs. "Mouser allows us to expand our reach to embedded design engineers and give them more channels and resources, especially at the design and testing phases," said Lance Laing, Vice President of US Sales for Airgain. "Ultimately, Airgain wants to be found where the design engineer is looking, and Mouser, one of the world's largest online distributors of electronic components, allows us to do that." "

08:05 EDT Genetic Technologies reports Q3 cash receipts A$1.8M - Commenting on the Company's quarterly performance, Chief Executive Officer Simon Morriss said: "The team is making remarkable progress, especially in unlocking areas such as the pathway to profitability, largely driven by the growing acceptance of geneType in Australia and the USA. Additionally, our new digital marketing efforts are delivering unprecedented levels of consumer engagement, and we are poised to significantly boost sales in the near future. The continuous rise in geneType adoption, coupled with enhanced brand engagement, is not only steering the company towards our profitability goals, but also positively impacting lives by identifying individuals at risk of diseases earlier, improving health outcomes for millions worldwide." At the end of March 2024, the Company had A$1.8 million in cash and cash equivalents. Cash receipts from customers for the quarter were A$1.83 million. Cash outflow for operating activities was A$2.6 million.

07:48 EDT Guru Organic Energy announces partnership with Jay Du Temple - GURU Organic Energy announces a partnership with Quebec comedian and host Jay Du Temple. GURU will notably be the content partner for Jay Du Temple's FIN Canadian tour, with Jay becoming a GURU shareholder and brand ambassador. Carl Goyette, President and CEO of GURU, said: "We're proud to welcome Jay, a rising star on the Quebec comedy scene, to the GURU family. We've known Jay since his early days on television, and we've followed his impressive on-stage journey in recent years. Jay embodies GURU's values as an authentic, accessible artist, through his two passions: the stage and sports. As fun, humor and sport take on greater importance for GURU, we sincerely believe that Jay has the potential to make a positive impact on the brand's position in Quebec."

07:47 EDT Invivyd cuts 14 positions, expects to end 2024 with at least $75M in cash - Invivyd, announced that following a comprehensive strategic review, the company is improving its projected 2024 year-end cash position by approximately $20 million to $25 million. Invivyd now expects to end 2024 with at least $75 million in cash and cash equivalents. "The Executive Committee of the Board of Directors has been working very closely with the management team to ensure that we are investing the company's resources in the areas that have the greatest potential to deliver appreciable benefits for patients and shareholders," said Marc Elia, Chairman. "Following a comprehensive strategic review which was conducted over the past several weeks, we were able to reallocate resources to support the launch of PEMGARDA, bolster our ability to deliver novel pipeline monoclonal antibody candidates, and further strengthen our balance sheet going forward. We look forward to sharing more details on our financials and our commercial progress when we report Q1 results in May." The improvements were primarily achieved through cash optimization in clinical operations and chemistry, manufacturing and controls. Fourteen full-time positions were eliminated in connection with the changes. Invivyd continues to anticipate 2024 PEMGARDA net product revenue in the range of $150 million to $200 million.

07:46 EDT Amesite launches AI, technical training programs at Volunteer State College - Amesite announced the launch of non-degree AI and technical training programs for industry certification and workforce development in partnership with Volunteer State Community College. Dr. Ann Marie Sastry, CEO of Amesite, said, "We are pleased to be able to partner with a growing number of colleges across the nation, including Vol State. Tennessee is among the top ten states in population growth and Amesite's footprint in high growth regions is a key part of our strategy. Workforce readiness is essential in the competition for talent and we are confident that Vol State will be successful in their ambitions to drive economic success for the region."

07:43 EDT Maravai Lifesciences subsidiary, Lonza enter license and supply pact for capping - TriLink BioTechnologies, a Maravai LifeSciences company, has signed a non-exclusive license and supply agreement with Lonza. According to the terms of the agreement, TriLink will supply its patented CleanCap M6, CleanCap AG 3'OMe, CleanCap AG, and CleanCap AU cap analogs for use in Lonza's global mRNA development and manufacturing services, from pre-clinical through Phase III programs. CleanCap technology is a one-pot solution with over 95% capping efficiency that streamlines mRNA production processes when compared to legacy capping methods.

07:43 EDT nCino's Cloud Banking Platform selected by Libro Credit Union - nCino announced that Libro Credit Union has selected nCino's Cloud Banking Platform to empower its employees through data, achieve faster time to value and create a smoother experience for customers. "We're proud to partner with Libro on their journey to enhance the banking experience for their Owners," said Greg Wipke, Vice President of Sales, Canada at nCino. "When it comes to operational efficiency, nCino offers Libro a user-friendly front-end while simultaneously allowing for better collaboration and knowledge sharing on the back-end for employees. By decreasing time to funding with nCino, Libro will be able to have an even greater impact on its communities, and we're excited to be part of that as well."

07:41 EDT Tenax Therapeutics announces new U.S. patent covering use of levosimendan - Tenax Therapeutics announced that the United States Patent and Trademark Office, USPTO, has granted the Company a patent covering the use of TNX-103, TNX-102, TNX-101, the active metabolites of levosimendan and various combinations of cardiovascular drugs with levosimendan when used to improve exercise performance in PH-HFpEF patients, entitled: "LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION." "Expanding our intellectual property estate for levosimendan is a strategic priority for Tenax. We are committed to protecting the future commercial value of our innovative PH-HFpEF treatment," said Chris Giordano, President & Chief Executive Officer of Tenax Therapeutics. "The important, additional IP protection this patent provides will help us maximize the value of levosimendan as we seek to address one of the largest unmet needs in cardiovascular medicine today."

07:40 EDT BioRestorative Therapies announces commercial agreement with Cartessa - BioRestorative Therapies announced that it has entered into a five-year exclusive supply agreement with Cartessa Aesthetics, a leading North American based aesthetic company focused on delivering best-in-class technologies and unparalleled end-to-end professional customer support. The goal of this transformative agreement is to combine BioRestorative's deep cell-based biologics experience, and formulation and clinical manufacturing expertise, with Cartessa's extensive professional aesthetics market reach, and marketing and distribution capabilities. As part of the exclusive five (5)-year agreement, BioRestorative has agreed to supply pre-set minimum quantities of finished vials of its initial cell-based biologic commercial product to Cartessa annually as private label under Cartessa's Chronos ExoCR mark.

07:39 EDT Virpax Pharmaceuticals reports results from Probudur rat study - Virpax Pharmaceuticals announced results for a Maximum Tolerated Dose, or MTD, study in Sprague-Dawley Rats for Probudur. Probudur is Virpax's injectable long-acting liposomal bupivacaine formulation that is injected at the wound site. Probudur is being developed to significantly reduce or eliminate the need for opioids after surgery in approved indications. Probudur is a local anesthetic that binds to the sodium channel, preventing pain signals from reaching the brain. In pre-clinical trials, Probudur has shown long duration pain control for at least 96 hours, with a rat incisional model demonstrating analgesia for up to five days and in vitro studies demonstrating a slow release of bupivacaine that lasted for up to six days. The study was designed to determine the MTD of free bupivacaine, Probudur, and Probudur plus free bupivacaine when administered as a single subcutaneous injection to the wound. Probudur, with its liposomal formulation, is intended to provide both immediate and extended pain relief at the wound site. The dosing ranges were selected based on a prior preliminary study. All doses of Probudur were well-tolerated. There were no noteworthy effects on body weight, clinical chemistry, hematology, or coagulation. It was also observed that bupivacaine appears to be less toxic in the presence of liposomes than when administrated as a free drug. Histopathology was conducted on the injection site and all treatment groups showed some changes which were minimal to moderate in severity. Effects were slightly more pronounced at the high dose of Probudur. In vivo MTD studies in rats indicated that Probudur provided a better therapeutic window as compared to free bupivacaine.

07:37 EDT Altus Power announces CEO transition - Yesterday morning, the company stated: "Altus Power announced today that the Board of Directors has accepted the resignation of Lars Norell as a co-CEO and as a director of the Company, effective April 26, 2024, and has appointed Gregg Felton as sole Chief Executive Officer of the Company. Mr. Felton will assume all of the duties formerly performed by Mr. Norell. The Company is reaffirming our full year guidance for 2024, which it announced on March 14, 2024 and will discuss its outlook and strategy at its first Investor Day on May 14, 2024."

07:34 EDT Senseonics Eversense granted integrated CGM designation by FDA - Senseonics announced that Eversense has been granted an integrated CGM, or iCGM, designation by the FDA. Eversense has been authorized to be marketed as an iCGM through the FDA's De Novo pathway, by establishing the special controls that will serve as a predicate device for 510(k) submissions in the future for devices of the same type.

07:33 EDT PayPal CEO 'encouraged' by progress team is making - President and CEO Alex Chriss said: "We delivered a solid set of results in Q1 and I'm encouraged by the progress the team is making against PayPal's go-forward strategy and in strengthening our foundation. 2024 remains a transition year and we are focused on execution - driving our key strategic initiatives, realizing cost savings, and reinvesting appropriately to position the company for consistent, high-quality profitable growth in the future."

07:32 EDT Silver Tiger provides update on pre-feasability study drilling on Stockwork - Silver Tiger Metals provided an update on the Company's ongoing Pre-Feasibility Study drilling program on the Stockwork gold deposit on its El Tigre Project in Sonora, Mexico. Silver Tiger has completed 23,500 metres of a 25,000 metre drilling program focused on expanding the Mineral Resource, up-grading the classification, completing metallurgical testwork and geotechnical studies as it progresses from an exploration to a development project. The value-added PFS progress is on schedule for publication in H2-2024. Three main areas of the Stockwork gold deposit are being targeted and show potential for expansion: the footwall, the hanging wall and bottom 'keel'. After releasing the first 75 drill holes of the program, the Company is pleased to announce conversion, expansion and derisking of the potential 'Starter Stockwork Zone'. The Stockwork gold deposit, comprised of the Footwall, Hanging Wall and high-grade Keel Zones, is seen in the below highlighted intercepts: Drill hole ET-23-541: 79.5 metres grading 0.75 g/t gold equivalent or 56.1 g/t silver equivalent from 92.5 to 172.0 metres, consisting of 0.52 g/t gold and 17.4 g/t silver INCLUDING 26.5 metres grading 1.19 g/t gold equivalent or 89.3 g/t silver equivalent from 94.0 to 120.5 metres consisting of 1.08 g/t gold and 8.0 g/t silver in the Hanging Wall Zone. Drill hole ET-23-543: 40.2 metres grading 1.21 g/t gold equivalent or 90.7 g/t silver equivalent from 148.0 to 188.2 metres, consisting of 0.84 g/t gold and 27.9 g/t silver INCLUDING 23.0 metres grading 1.72 g/t gold equivalent or 129.3 g/t silver equivalent from 152.0 to 175.0 metres consisting of 1.22 g/t gold and 37.9 g/t silver in the Keel Zone. Drill hole ET-23-548: 71.0 metres grading 0.67 g/t gold equivalent or 50.6 g/t silver equivalent from 0.0 to 71.0 metres, consisting of 0.62 g/t gold and 3.9 g/t silver INCLUDING 18.5 metres grading 1.36 g/t gold equivalent or 101.7 g/t silver equivalent from 39.5 to 58.0 metres consisting of 1.32 g/t gold and 2.4 g/t silver in the Footwall Zone. Drill hole ET-23-550: 81.1 metres grading 0.94 g/t gold equivalent or 70.3 g/t silver equivalent from 43.5 to 124.5 metres, consisting of 0.90 g/t gold and 3.0 g/t silver INCLUDING 32.0 metres grading 1.36 g/t gold equivalent or 102.1 g/t silver equivalent from 54.0 to 86.0 metres consisting of 1.31 g/t gold and 3.6 g/t silver in the Footwall Zone and 21.0 metres grading 0.68 g/t gold equivalent or 50.1 g/t silver equivalent from 0.0 to 21.0 metres, consisting of 0.53 g/t gold and 10.5 g/t silver at the top of the hole. Silver Tiger's CEO, Glenn Jessome, stated, "As we continue receiving promising assay results, it is apparent that the developing "Footwall" and "Keel Zones" shows excellent grade and continuity. The results may increase the updated MRE associated with the PFS-level study, as well as further de-risk the project."

07:29 EDT Immunic announces data from EMPhASIS trial published - Immunic announced that data from its phase 2 EMPhASIS trial of lead asset, vidofludimus calcium, or IMU-838, in patients with relapsing-remitting multiple sclerosis, or RRMS, has been published online on April 25 in Neurology Neuroimmunology & Neuroinflammation, an official journal of the American Academy of Neurology. Given that both doses of 30 mg and 45 mg of vidofludimus calcium showed comparable activity on multiple endpoints, the trial enrolled an additional cohort of patients to receive a lower dose of vidofludimus calcium in order to further investigate a dose-response relationship by extending the trial to a broader dose range. Study cohort 2 explored the dose of 10 mg of vidofludimus calcium versus placebo. Extended results from the pooled EMPhASIS data were summarized in more detail in this latest peer-reviewed article. The pooled data showed that, compared to placebo, vidofludimus calcium suppressed the development of new CUA MRI lesions with daily doses of 30 mg and 45 mg up to week 24 by 76% and 71%, respectively. In addition, compared to placebo, vidofludimus calcium suppressed the development of Gd+ lesions with daily doses of 30 mg and 45 mg up to week 24 by 78% and 74%, respectively. Such robust anti-inflammatory effects were not seen with 10 mg, establishing 30 mg as the lowest effective dose. Serum neurofilament light chain, or NfL, which is thought to correlate with neuronal destruction, decreased in a dose-dependent manner up to the highest tested dose of vidofludimus calcium by 9%, 18% and 26% compared to placebo, respectively, suggesting that the effect on NfL has a different dose-response pattern which contrasts with that observed with new CUA or Gd+ by MRI lesions. Increases in disability over a pre-defined disability change threshold during the double-blind treatment period were confirmed after 12 or 24 weeks, designating them confirmed disability worsening events. The number of patients who had confirmed 12- or 24-weeks CDW events was 3.7% for patients receiving placebo and only 1.6% for patients receiving any dose of vidofludimus calcium. Finally, the pooled data set also reinforced that vidofludimus calcium was well-tolerated, in general, and that its safety profile was similar to the placebo group. Across cohorts 1 and 2, a total of 268 patients were randomized to 10 mg, 30 mg, or 45 mg of vidofludimus calcium or placebo.

07:28 EDT Lindblad Expeditions acquires Wineland-Thomson Adventures - Lindblad Expeditions has acquired adventure travel group Wineland-Thomson Adventures through its subsidiary Natural Habitat. Wineland-Thomson consists of several adventure travel offerings, including Tanzania safari specialist Thomson Safaris, which has been operating for over 40 years and focuses on leading socially responsible and positively impactful light-treading safari tours. The acquisition also includes the historic Gibb's Farm lodge. Gibb's Farm is a historic organic farm and family coffee plantation covering over 80 acres on the forested outer slopes of the Ngorongoro Crater. Wineland-Thomson operations will continue as stand-alone offerings.

07:26 EDT Entourage Health says 'resolve remains optimistic' - The company said, "The key to Entourage's success in 2024 lies in the strategic alignment of its brands, the diverse range of its products, and the dedication of its teams. Navigating the dynamic cannabis landscape is central to the Company's aim of achieving year-over-year growth. A key factor in this growth is Entourage's strategic partnerships with external suppliers. These partners are meticulously chosen for their commitment to excellence, efficiency, and their alignment with the Company's core values. The transformative changes implemented in 2023 positively impacted Entourage's business fundamentals as it improved cost savings, invested in manufacturing, and developed a data-driven approach, solidifying the Company for sustainable growth. Entourage carefully analyzes profitability metrics to guide financial success, ensuring every decision enhances overall financial health and operational effectiveness. Despite the challenges of the Canadian cannabis industry and regulatory complexities, Entourage's resolve remains optimistic. Through proactive engagement and strategic foresight, the Company is poised to overcome these hurdles and capitalize on emerging opportunities, unlocking new avenues for growth and expansion in the years ahead."

07:22 EDT NanoXplore announces closing of C$60M creidt facility - NanoXplore announces the closing of a new credit facility with the Royal Bank of Canada. Under the agreement, RBC will provide NanoXplore's subsidiaries with up to C$60M. The credit facility, inclusive of an existing equipment lease and other financial products, will provide a C$10M revolving credit line, up to C$45M in equipment leasing and C$5M in term loans and will carry interest rates similar to those the Corporation currently pays. The new credit facility will allow for the reimbursement of existing loans of approximately C$4.7M with other lenders. Today's announcement is a significant step forward in completing financial requirements to meet capex needs. The Corporation is also in the process of finalizing up to C$80M in non-dilutive government incentives that will cover most of the remaining portion of capital needs for execution of the five-year strategic plan.

07:20 EDT Aslan Pharmaceuticals to host KOL panel discussion on Dupilumab - ASLAN Pharmaceuticals announced that it will host a virtual Key Opinion Leader, KOL, Event, "Treatment Options for Atopic Dermatitis Patients with an Inadequate Response to Dupilumab: Exploring the Potential of Eblasakimab in this Sizable New Market." The event will feature a discussion with Lisa Beck, MD from University of Rochester, Peter Lio, MD from Northwestern University, and Raj Chovatiya, MD, PhD from Rosalind Franklin University Chicago Medical School, moderated by Seth Orlow, MD, PhD from New York University, on the recently announced positive interim results from ASLAN's Phase 2 TREK-DX study of eblasakimab, a potential first-in-class biologic candidate, in patients with moderate-to-severe atopic dermatitis that had previously been treated with dupilumab. Panelists will discuss this growing new market and the treatment options available to patients with an inadequate response to dupilumab. Company management will also present new data from the interim analysis of the TREK-DX study.

07:18 EDT Sonic Automotive promotes Dino Bernacchi to Chief Marketing Officer - Sonic Automotive announced the retirement of Rachel Richards as the company's Chief Marketing Officer. Dino Bernacchi will be promoted to Chief Marketing Officer of the company effective May 1. Rachel Richards joined Sonic Automotive in 2006 as the company's Vice President of Retail Strategy and became the company's first Chief Marketing Officer in 2014. Dino Bernacchi will replace Richards upon her retirement. Bernacchi joined the company in October 2021 as the Chief Marketing Officer for EchoPark Automotive.

07:18 EDT PyroGenesis signs initial contract with aerospace entity in Spain - PyroGenesis Canada announces the signing of an initial contract with an aerospace entity in Spain for the sale of PyroGenesis' titanium metal powder for use in additive manufacturing. The client is engaged in the development of advanced aeronautics technologies for the European aerospace industry. The name of the client will remain anonymous for confidentiality reasons. This new order is for our titanium metal powder with a particle size range of 15-63microm. This powder cut range is ideally suited for laser bed additive manufacturing methods, including Direct Metal Laser Sintering or Selective Laser Melting, which are widely recognized for their precision and strength in creating complex metal compounds.

07:17 EDT ProMIS Neurosciences publishes study highlighting oligomers in journal bioRxiv - ProMIS Neurosciences announced the publication of a paper titled, "Relationship between therapeutic activity and preferential targeting of toxic soluble aggregates by amyloid-beta-directed antibodies," in the online journal, bioRxiv. The study characterized and compared the binding profile of various amyloid-beta-directed antibodies to monomers, soluble oligomers and insoluble Ab fibrils. The results indicate that selectivity for soluble toxic Ass oligomers may be a driver of clinical efficacy and indicated that PMN310 displayed the greatest degree of oligomer selectivity. "The data in this publication highlight PMN310's high degree of selectivity for toxic Ab oligomers and its differentiation from other Ab-directed antibodies," stated Neil Warma, Chief Executive Officer of ProMIS Neurosciences. "We believe that PMN310's ability to avoid both monomer and plaque binding has the potential to improve efficacy and reduce the risk of amyloid-related imaging abnormalities, a key indicator of edema and microhemorrhage risk associated with plaque binding antibody therapies currently on the market and in development. We look forward to the top-line data readout for our Phase 1a study in the coming months and to advancing PMN310 into a Phase 1b multiple ascending dose study in AD patients."

07:15 EDT BJ's Wholesale announces three new locations in Florida and New York - BJ's Wholesale announced the three newest clubs in 2024: Staten Island, New York, BJ's 49th location in New York, located in Bricktown Centre; Brooksville, Florida, the company's 40th club in Florida; St. Johns, Florida, located near Jacksonville, the company's 41st club in Florida. Each new BJ's Wholesale Club location is expected to create approximately 150 jobs and hiring is expected to start soon for these new locations.

07:14 EDT Eton Pharmaceuticals submits ET-400 NDA to FDA - Eton Pharmaceuticals announced the submission of a New Drug Application to the U.S. Food and Drug Administration for approval of ET-400, Eton's proprietary patented formulation of hydrocortisone oral solution. The Company expects the application to be assigned a 10-month FDA review, allowing for potential approval and launch in the first quarter of 2025. Eton has been issued a patent by the U.S. Patent and Trademark Office on ET-400, which expires in 2043 and has additional patent applications under review.

07:10 EDT Perspective Therapeutics selected by FDA to participate in CDRP program - Perspective Therapeutics announces the selection of investigational product (212Pb)VMT-alpha-NET for the treatment of certain patients with neuroendocrine tumors by the U.S. Food and Drug Administration, FDA, to participate in the Chemistry, Manufacturing, and Controls, CMC, Development and Readiness Pilot, CDRP, program. "Our priority is to expeditiously investigate whether (212Pb)VMT-alpha-NET can benefit patients beyond current standard of care in NETs, and if so, be ready to supply patients," said Thijs Spoor, Perspective Therapeutics' CEO. "We are grateful to be able to partner with the FDA to that end, and look forward to increased interactions with the FDA on manufacturing readiness."

07:08 EDT WELL Health Technologies announces collaboration with Microsoft - WELL Health Technologies is pleased to announce it is collaborating with Microsoft to accelerate healthcare's digital transformation. This five-year agreement is set to accelerate the digital transformation of healthcare delivery across North America and beyond, integrating Microsoft Cloud and AI capabilities with WELL's comprehensive digital health platform to innovate and enhance the healthcare experience for both providers and patients. A key focus will be to substantially elevate WELL's scalability and flexibility as part of its offerings, especially as its organic growth accelerates and it aims to help large enterprise clients such as those in public sector.

07:07 EDT Alnylam, Medison Pharma expand partnership - Medison Pharma and Alnylam Pharmaceuticals announced a further expansion of their existing partnership in Central & Eastern Europe and Israel, to also include selected markets in LATAM and APAC and additional international markets. Medison, the creator and leader of the multi-regional partnership category, has established a unique, unified commercialization platform in international markets, particularly for the treatment of rare and severe diseases. Medison is the only partner that focuses solely on the most innovative therapies.

07:05 EDT Harmony Biosciences acquires Epygenix Therapeutics for $35M in cash - Harmony Biosciences announced the acquisition of Epygenix Therapeutics, Inc., accelerating its growth strategy by adding a rare epilepsy franchise to its expanding late-stage pipeline of innovative CNS assets. Under the terms of the definitive agreement, Harmony paid $35M in cash with the potential for payments of up to $130M based on development and regulatory milestones. In addition, there are potential payments of up to $515M if certain sales milestones are achieved.

07:02 EDT McDonald's reports Q1 U.S. SSS up 2.5% - Global comparable sales increased 1.9%, reflecting positive comparable sales in the U.S. and International Operated Markets segment. Comparable sales in the International Developmental Licensed Markets segment were slightly negative as the segment continued to be impacted by the war in the Middle East: U.S. increased 2.5%. International Operated Markets segment increased 2.7%. International Developmental Licensed Markets segment decreased 0.2%.Consolidated revenues increased 5% (4% in constant currencies).Systemwide sales increased 3% (3% in constant currencies).

06:51 EDT Restaurant Brands sees FY24 capital expenditures $300M - RBI continues to expect consolidated capital expenditures, tenant inducements and incentives of approximately $300M and adjusted interest expense, net, between $555M and $565M. RBI now expects Segment G&A for 2024 between $665M and $685M, including share-based compensation and non-cash incentive compensation expense between $180M and $190M.

06:36 EDT Restaurant Brands reports additional $300M investment to modernize Burger King - Burger King announced an additional $300M investment to accelerate the modernization of Burger King restaurants across the U.S. This comes after BK announced $250M in modern image, technology and new kitchen equipment in September 2022 as part of its Reclaim the Flame plan, and a further $500M to accelerate the reimaging of more than 600 Carrols Restaurant Group owned Burger King restaurants following the pending acquisition of Carrols. The September 2022 Reclaim the Flame plan also included $150M in incremental digital and media investments through 2024 followed by an agreement with franchisees to increase their investments in advertising from 2025-2028 should certain franchisee profitability metrics be achieved.

06:27 EDT IN8bio begins dosing in Phase 2 trial of INB-400 in newly diagnosed glioblastoma - IN8bio announced that the first patient in its Phase 2 clinical trial evaluating INB-400 in patients with newly diagnosed glioblastoma multiforme - GBM - has been successfully dosed at the Cleveland Clinic in Ohio. INB-400 is the company's first autologous gamma-delta T cell therapy product candidate genetically engineered to survive chemotherapy and maintain the natural ability to recognize, engage and kill cancer cells when dosed along with current, standard-of-care treatments such as temozolomide. Arm A of the INB-400 trial is expected to enroll up to 40 patients. INB-400 was granted Orphan Drug Designation by the FDA in 2023. The Phase 2 study will evaluate the safety and tolerability of INB-400 in patients with newly diagnosed GBM in combination with TMZ. The primary endpoint of the study is overall survival rate at 12 months. Secondary endpoints include safety and tolerability, overall response rate, time to progression, and progression-free survival.

06:26 EDT Sandoz shareholders approve all resolutions proposed by board - Sandoz announced that its shareholders approved all proposals of the Board of Directors at its Annual General Meeting, including the Annual Financial Statements and Consolidated Financial Statements as well as the report on non-financial matters for the 2023 financial year. The shareholders in attendance, together with the votes represented by the independent proxy, represented 79.23% of registered shares.

06:25 EDT MannKind to proceed with Phase 1 Nintedanib Dpi (Mnkd-201) study - MannKind announced that it will proceed with a first-in-human Phase 1 study of nintedanib DPI (MNKD-201) for pulmonary fibrotic diseases, including idiopathic pulmonary fibrosis.

06:21 EDT American Strategic Investment Co. accelerating diversification through divesting - American Strategic Investment Co. intends to accelerate its efforts to evolve and diversify its business. The company has started the process to market for sale its 9 Times Square Midtown Manhattan asset. In addition, the company intends to market for sale its properties located at 123 William Street and 196 Orchard Street. These strategic dispositions are in furtherance of the company's repositioning of the company's investment portfolio and expanded business plan to invest in assets beyond Manhattan real estate. The company has also secured an amendment of the loan on 9 Times Square, which extends the maturity date to October 2024, with the option of an additional extension to year-end 2024, to facilitate the proposed sale of the property.

06:18 EDT Taylor Morrison sees Q2 home closings 3,000 - Sees Q2 average closing price $605,000. Sees Q2 home closings gross margin 23.5%. Ending active community count is expected to be 330-340. Sees Q2 effective tax rate 25%.

06:16 EDT Walmart announces launch of bettergoods, a private food brand - Walmart announced its latest private brand innovation, bettergoods: "a new elevated experience that delivers quality, unique, chef-inspired food at an incredible value," the company said. Bettergoods marks Walmart's largest private brand food launch in 20 years and the fastest food private brand Walmart has brought to market. "Today's customers expect more from the private brands they purchase - they want affordable, quality products to elevate their overall food experience. The launch of bettergoods delivers on that customer need in a meaningful way," said Scott Morris, senior vice president, private brands, food and consumables, Walmart. "Bettergoods is more than just a new private brand. It's a commitment to our customers that they can enjoy unique culinary flavors at the incredible value Walmart delivers." Bettergoods items range from under $2 to under $15, with most products available for under $5.

06:09 EDT Aurinia Pharmaceuticals: FDA approves updated LUPKYNIS label - Aurinia Pharmaceuticals announced that the FDA has approved a label update for LUPKYNIS. The updated label no longer includes language indicating that the safety and efficacy of LUPKYNIS has not been established beyond one year. The label now includes three-year data from the AURORA 2 double-blind, placebo-controlled extension study, which assessed the long-term safety and tolerability of LUPKYNIS in combination with mycophenolate mofetil and low-dose glucocorticoids, compared with MMF and low-dose glucocorticoids alone, in adults with active lupus nephritis who completed the Phase 3 AURORA 1 clinical trial.

05:41 EDT Gogoro signs MOU with Sumitomo Mitsui, Sumitomo to accelerate expansion - Gogoro (GGR) announced the signing of a non-binding memorandum of understanding, or MOU, the first step in establishing a new partnership with Sumitomo (SSUMY) and Sumitomo Mitsui Finance (SMFG) to accelerate Gogoro's global business expansion while providing Sumitomo and SMFL with new unique opportunities to expand their mobility business and second life battery use cases using Gogoro Smart Batteries and battery swapping.

05:32 EDT Stellantis backs FY24 adjusted operating income margin view of double-digits - The company said, "The Company is reiterating a minimum commitment of double-digit Adjusted operating income (AOI) margin in 2024, as well as positive Industrial free cash flow, despite macroeconomic uncertainties."

05:19 EDT Alvotech, Teva to manufacture biosimilar to Humira for Quallent - Alvotech (ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical (TEVA), disclosed that under the recently announced U.S. strategic partnership agreement, Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira for Quallent Pharmaceuticals, in alignment with its U.S. commercialization agreement with Teva. The interchangeable biosimilar will be distributed under Quallent's private label. In August 2020, Alvotech and Teva entered into a strategic partnership for the exclusive commercialization of five of Alvotech's biosimilar product candidates, and in August 2023 the partners extended the partnership to include two additional biosimilars and two new presentations of previously partnered products. Alvotech handles development and manufacturing, and Teva is responsible for U.S. commercialization, which leverages Teva's experience and sales and marketing infrastructure. Alvotech's high concentration interchangeable biosimilar to Humira was the first biosimilar approved under the strategic partnership, and Teva expects to launch it to patients in the U.S. imminently.

05:08 EDT Ambarella, Neusoft Reach forge strategic partnership - Neusoft Reach Automotive Technology, a subsidiary of Neusoft specializing in intelligent vehicle technology, and Ambarella announced the establishment of a strategic partnership at the Beijing Auto Show. This cooperation is based on the resources and advantages of both parties in areas such as automotive software, autonomous driving technology, electrification, and AI system-on-chip, or SoC, products. Through this strategic partnership, the companies plan to jointly promote and explore product technology and market development and realize shared opportunities for collaborative innovation and development. Leveraging its more than 20 years of research and development experience in autonomous-driving AI visual perception algorithms, Neusoft Reach has utilized Ambarella's CVflow portfolio of AI SoCs with the independently developed Neusoft Reach neural network algorithms. Since the mass production of the first integrated product, cooperatively launched in 2021, and subsequent jointly developed products such as driver monitoring system and front advanced driver assistance system modules, Neusoft Reach and Ambarella have already achieved cooperation in multiple key technology areas. These collaborations not only facilitate the implementation of intelligent driving functions at level L2 and above, but also include solid provisions for the iterative upgrade of safety in intelligent vehicles. Most recently, Neusoft Reach's third-generation forward-facing intelligent camera, X-Cube 3.0, is powered by Ambarella's CV22 AI vision SoC. This camera's AI perception algorithms, targeting L2+ autonomy levels, and processed by Ambarella's CV22 SoCs, have been mass-produced and deployed by automotive OEMs. By adopting this jointly developed platform, OEMs are able to deploy product technologies and solutions in their passenger vehicles. Currently, Neusoft Reach is collaborating with Ambarella on a new generation of AI domain control solutions, actively advancing the joint development and cooperation with Ambarella's latest family of AI SoCs in the field of intelligent driving. This cooperation will further optimize the performance and efficiency of current intelligent driving systems, and Neusoft Reach and Ambarella's shared "algorithm-first" philosophy is being fully practiced and validated in this process.